N@N

Isotechnika announces new Chairman of the Board and Addition of new Board of Director member

_{//health-fitness.news-articles.net/content/2009/ .. nd-addition-of-new-board-of-director-member.html}
^{Published in Health and Fitness on Thursday, June 25th 2009 at 10:36 GMT, Last Modified on 2009-06-25 10:38:01 by Market Wire}  

 EDMONTON, June 25 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA), announced that, effective June 22, 2009, Mr. Jonathan Ross Goodman, has assumed the position as Chairman of the Board of Directors. Mr. Goodman is the founder, President & CEO of Paladin Labs Inc., a Toronto Stock Exchange listed, specialty pharmaceutical company with a market capitalization in excess of $300 million dollars. Paladin has achieved 13 consecutive years of record revenues with revenues growing at a compounded annual growth rate of 111% since the company's founding in 1996. Paladin has been recognized by the National Post as one of Canada's 50 Best Managed Companies, by Profit Magazine as one of Canada's fastest growing technology companies, by Deloitte as a Canadian Technology Fast 50, and, most recently, by the Quebec Federation of Chambers of Commerce as best Quebec company in trade and distribution (Mercuriades). Mr. Goodman is a recipient of the Globe and Mail's Top 40 Under 40 Award and was named Quebec Entrepreneur of the Year in the Life Sciences by the National Post and Ernst & Young. Mr. Goodman is a member of the Board of Directors of the Canadian Chamber of Commerce, Medicago Inc., and NeurAxon Inc. and teaches an MBA course at McGill University on pharmaceutical entrepreneurship. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honors. Additionally, Mr. Goodman holds an LL.B. and MBA from McGill University. Mr. Goodman is a member of the Bars of New York and Massachusetts. Mr. Goodman replaces Mr. Donald Schurman who has resigned his position as Chairman and Director of Isotechnika Pharma Inc. Additionally, Isotechnika Pharma is pleased to announce the addition of new Board member, Ms. Nancy Harrison, effective June 22, 2009. Nancy is a co-founder of MSI Methylation Sciences Inc. and is former Senior Vice President of Ventures West Management Inc. Ms. Harrison joined Ventures West in 1993 and focused her efforts on the life sciences sector. Ms. Harrison is one of the most experienced biotech investors in the Canadian venture capital industry and was instrumental in Ventures West's involvement with Angiotech Pharmaceuticals, Inc. (TSE IPO, 1997; NASDAQ, 2000) and AnorMed, Inc. (TSE IPO, 1999) to name a few. In addition to her role at MSI, Ms. Harrison currently donates her time as a Director of several not for profit groups including the Family Services of the North Shore and Providence Health Care. She is a past winner of the Globe and Mail's Top 40 Under 40 Award, a national program that recognizes the professional and academic achievements of individuals under the age of 40. Ms. Harrison holds a Bachelor of Applied Science (Honours) from Queen's University and a MBA from McGill University. "We are pleased to welcome Nancy and Jonathan to our Board, and we look forward to their guidance as we embark on a new direction for the company" stated Dr. Robert Foster, President and CEO of Isotechnika Pharma. "In addition, we would like to thank Mr. Donald Schurman for his years of dedicated service to the company". The company also announces the resignation of Clemens Kaiser, Executive Vice President and Chief Marketing Officer. Mr. Kaiser has been with Isotechnika since October of 2007 and leaves to pursue other interests. About Isotechnika Pharma Edmonton-based Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential will exceed $4 billion annually in sales for calcineurin inhibitors such as voclosporin by 2010. Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at [ www.isotechnika.com ] or [ www.SEDAR.com ]. Forward-Looking Statements This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. %SEDAR: 00010508E 

For further information: Dr. Robert Foster, President & CEO, Isotechnika Pharma Inc., (780) 487-1600 (247), (780) 484-4105 (fax), [ rfoster@isotechnika.com ]; Mr. Dennis Bourgeault, Chief Financial Officer, Isotechnika Pharma Inc., (780) 487-1600 (226), (780) 484-4105 (fax), [ dbourgeault@isotechnika.com ]